Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 1/20 | 0.74 |
| ▸ | ACACA | Q13085 | 1/20 | 0.74 |
| ▸ | ACLY | P53396 | 1/20 | 0.44 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.38 |
| ▸ | GPR84 | Q9NQS5 | 5/20 | 0.35 |
| ▸ | PPARA | Q07869 | 4/20 | 0.34 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | TTR | P02766 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.33 |
| ▸ | PPARG | P37231 | 1/20 | 0.33 |
| ▸ | HTR2B | P41595 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3751463 | 0.93 | ACACB (0.84) | ACACBACACAACLYFFAR4FFAR1 | |
| SCHEMBL6196497 | 0.93 | ACACB (0.69) | ACACBACACAACLYFFAR4FFAR1 | |
| SCHEMBL3748635 | 0.91 | ACACB (0.88) | ACACBACACAACLYFFAR4FFAR1 | |
| SCHEMBL12094483 | 0.91 | ACACB (0.88) | ACACBACACAACLYFFAR4FFAR1 | |
| SCHEMBL186486 | 0.87 | ACACB (0.96) | ACACBACACAACLYFFAR4FFAR1 | |
| SCHEMBL205270 | 0.87 | ACACB (0.96) | ACACBACACAACLYFFAR4FFAR1 | |
| SCHEMBL10264689 | 0.87 | ACACB (0.62) | ACACBACACAACLYFFAR4FFAR1 | |
| SCHEMBL23348922 | 0.85 | ACACB (1.00) | ACACBACACAACLYFFAR4FFAR1 | |
| SCHEMBL186052 | 0.85 | ACACB (1.00) | ACACBACACAACLYFFAR4FFAR1 | |
| Bempedoic Acid SCHEMBL185768 | 0.85 | ACACB (1.00) | ACACBACACAACLYFFAR4FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2404890-A1 | Hydroxyl compounds and compositions for cholesterol management and related uses | Esperion Therapeutics Inc. (US) | 2012-01-11 | — | — | EP | disclosed |
| EP-2402300-A1 | Hydroxyl compounds and compositions for cholesterol management and related uses | Esperion Therapeutics Inc. (US) | 2012-01-04 | — | — | EP | disclosed |
| US-7838554-B2 | dyslipidemia; regulating lipid, lipoprotein, insulin, glucose levels in the blood; 6,9-Dihydroxy-2,2,13,13-tetramethyl-tetradecanedioic acid; 2,2,13,13-Tetramethyl-tetradecane-1,6,9,14-tetraol; 6,10-Dihydroxy-2,2,14,14-tetramethyl-pentadecanedioic acid; 2,2,14,14-Tetramethyl-pentadecane-1,6,10,15-tetraol | ESPERION THERAPEUTICS, INC. (US) | 2010-11-23 | — | — | US | disclosed |
| US-7838554-B2 | dyslipidemia; regulating lipid, lipoprotein, insulin, glucose levels in the blood; 6,9-Dihydroxy-2,2,13,13-tetramethyl-tetradecanedioic acid; 2,2,13,13-Tetramethyl-tetradecane-1,6,9,14-tetraol; 6,10-Dihydroxy-2,2,14,14-tetramethyl-pentadecanedioic acid; 2,2,14,14-Tetramethyl-pentadecane-1,6,10,15-tetraol | ESPERION THERAPEUTICS, INC. (US) | 2010-11-23 | — | — | US | disclosed |
| US-20090247489-A1 | dyslipidemia; regulating lipid, lipoprotein, insulin, glucose levels in the blood; 6,9-Dihydroxy-2,2,13,13-tetramethyl-tetradecanedioic acid; 2,2,13,13-Tetramethyl-tetradecane-1,6,9,14-tetraol; 6,10-Dihydroxy-2,2,14,14-tetramethyl-pentadecanedioic acid; 2,2,14,14-Tetramethyl-pentadecane-1,6,10,15-tetraol | ESPERION THERAPEUTICS, INC. | 2009-10-01 | — | — | US | disclosed |
| US-20090247489-A1 | dyslipidemia; regulating lipid, lipoprotein, insulin, glucose levels in the blood; 6,9-Dihydroxy-2,2,13,13-tetramethyl-tetradecanedioic acid; 2,2,13,13-Tetramethyl-tetradecane-1,6,9,14-tetraol; 6,10-Dihydroxy-2,2,14,14-tetramethyl-pentadecanedioic acid; 2,2,14,14-Tetramethyl-pentadecane-1,6,10,15-tetraol | ESPERION THERAPEUTICS, INC. | 2009-10-01 | — | — | US | disclosed |
| US-7576130-B2 | Tetramethyltetradecanetetraols as anticarcinogenic, anticholesterol, antidiabetic and hypotensive agents; metabolic disorders, peroxisome proliferator activated receptor associated disorder, Alzheimer's Disease, obesity, pancreatitis; increased HDL levels and lowers LDL levels; combination therapy | ESPERION THERAPEUTICS, INC. (US) | 2009-08-18 | — | — | US | disclosed |
| US-7576130-B2 | Tetramethyltetradecanetetraols as anticarcinogenic, anticholesterol, antidiabetic and hypotensive agents; metabolic disorders, peroxisome proliferator activated receptor associated disorder, Alzheimer's Disease, obesity, pancreatitis; increased HDL levels and lowers LDL levels; combination therapy | ESPERION THERAPEUTICS, INC. (US) | 2009-08-18 | — | — | US | disclosed |
| US-20080064661-A1 | Tetramethyltetradecanetetraols as anticarcinogenic, anticholesterol, antidiabetic and hypotensive agents; metabolic disorders, peroxisome proliferator activated receptor associated disorder, Alzheimer's Disease, obesity, pancreatitis; increased HDL levels and lowers LDL levels; combination therapy | ESPERION THERAPEUTICS, INC. | 2008-03-13 | — | — | US | disclosed |
| US-20080064661-A1 | Tetramethyltetradecanetetraols as anticarcinogenic, anticholesterol, antidiabetic and hypotensive agents; metabolic disorders, peroxisome proliferator activated receptor associated disorder, Alzheimer's Disease, obesity, pancreatitis; increased HDL levels and lowers LDL levels; combination therapy | ESPERION THERAPEUTICS, INC. | 2008-03-13 | — | — | US | disclosed |
| US-7335689-B2 | for example, 6,9-Dihydroxy-2,2,13,13-tetramethyl-tetradecanedioic acid, 2,2,13,13-Tetramethyl-tetradecane-1,6,9,14-tetraol, 6,10-Dihydroxy-2,2,14,14-tetramethyl-pentadecanedioic acid; treatment of Alzheimer's Disease, metabolic syndrome disorder, cancer, cardiovascular disease, diabetic nephropathy | ESPERION THERAPEUTICS, INC. (US) | 2008-02-26 | — | — | US | disclosed |
| US-7335689-B2 | for example, 6,9-Dihydroxy-2,2,13,13-tetramethyl-tetradecanedioic acid, 2,2,13,13-Tetramethyl-tetradecane-1,6,9,14-tetraol, 6,10-Dihydroxy-2,2,14,14-tetramethyl-pentadecanedioic acid; treatment of Alzheimer's Disease, metabolic syndrome disorder, cancer, cardiovascular disease, diabetic nephropathy | ESPERION THERAPEUTICS, INC. (US) | 2008-02-26 | — | — | US | disclosed |
| EP-1597223-A2 | HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | Esperion Therapeutics Inc. (US) | 2005-11-23 | — | — | EP | disclosed |
| WO-2004067489-A2 | HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | ESPERION THERAPEUTICS, INC. (US) | 2004-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064661-A1 | Tetramethyltetradecanetetraols as anticarcinogenic, anticholesterol, antidiabetic and hypotensive agents; metabolic disorders, peroxisome proliferator activated receptor associated disorder, Alzheimer's Disease, obesity, pancreatitis; increased HDL levels and lowers LDL levels; combination therapy | PNLIP, APOL1, NR1H3 | ACACB 657/4885ACACA 473/4885ACLY 1305/4885 |
| US-20090247489-A1 | dyslipidemia; regulating lipid, lipoprotein, insulin, glucose levels in the blood; 6,9-Dihydroxy-2,2,13,13-tetramethyl-tetradecanedioic acid; 2,2,13,13-Tetramethyl-tetradecane-1,6,9,14-tetraol; 6,10-Dihydroxy-2,2,14,14-tetramethyl-pentadecanedioic acid; 2,2,14,14-Tetramethyl-pentadecane-1,6,10,15-tetraol | PNLIP, GPR119, APOL1 | ACACB 871/4885ACACA 831/4885ACLY 1984/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.